Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.
Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.